surmount-1 tirzepatide obesity nejm 2022 weight loss percent GLP-1 Medications for Loss: Semaglutide vs vs Retat – Revolution Health & Wellness SURMOUNT-1 Tirzepatide Trial — 22.5%

As for heart disease risk markers: triglycerides dropped 37%, waist circumference shrank about 7.5 inches, blood pressure and inflammation markers (hsCRP) also improved

Telehealth followups can help adjust a plan if side effects occur or if symptoms dont improve as expected

Use centralized logging to ensure that decisions are based on data

High-protein, high-fiber, hydration and gut health products are also drawing particular interest, especially among younger shoppers

The performance improvement could partially stem from modified behavioral states

Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes and Obesity